NCT05518994View on ClinicalTrials.gov

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Astrocytoma of Brain
Interventions
DRUG

Tislelizumab plus Bevacizumab

200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.

Trial Locations (1)

450003

Henan Provincial People's Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Provincial People's Hospital

OTHER